Teleconference: Study of Tamoxifen and Raloxifene (STAR) P-2
April 19, 2010
Breast Cancer Prevention: Raloxifene as Effective as Tamoxifen with Fewer Side Effects
Raloxifene improved its effectiveness against noninvasive breast cancer, caused significantly less endometrial cancer and was significantly less toxic than tamoxifen. Full results of the Study of Tamoxifen and Raloxifene (STAR) P-2 trial in breast cancer prevention are discussed in this press conference by a panel of experts.
Download the teleconference (29.3 MB file; 42:41 minutes duration. Requires QuickTime).
No comments yet
AACR News 